Mometasone furoate cream reduces acute radiation dermatitis in patients receiving breast radiation therapy: results of a randomized trial
| Autor: | Anne Whitehead, Ruth Hornsby, David Charles Barber, Zakiyah Zain, Alison Sanneh, Andrew Hindley, Lisa Wood |
|---|---|
| Rok vydání: | 2014 |
| Předmět: |
Cancer Research
medicine.medical_specialty Erythema medicine.medical_treatment Administration Topical Skin Cream Mometasone furoate Breast Neoplasms Drug Administration Schedule law.invention Randomized controlled trial Double-Blind Method law medicine Clinical endpoint Humans Radiology Nuclear Medicine and imaging Pregnadienediols Radiation Emollients business.industry Dose fractionation Dermatology Life Quality Index Middle Aged Dermatology Radiation therapy Oncology Sample Size Female Dermatologic Agents Dose Fractionation Radiation medicine.symptom Radiodermatitis business Mometasone Furoate medicine.drug Topical steroid |
| Zdroj: | International journal of radiation oncology, biology, physics. 90(4) |
| ISSN: | 1879-355X |
| Popis: | Purpose We wanted to confirm the benefit of mometasone furoate (MF) in preventing acute radiation reactions, as shown in a previous study (Bostrom et al, Radiother Oncol 2001;59:257-265). Methods and Materials The study was a double-blind comparison of MF with D (Diprobase), administered daily from the start of radiation therapy for 5 weeks in patients receiving breast radiation therapy, 40 Gy in 2.67-Gy fractions daily over 3 weeks. The primary endpoint was mean modified Radiation Therapy Oncology Group (RTOG) score. Results Mean RTOG scores were significantly less for MF than for D ( P =.046). Maximum RTOG and mean erythema scores were significantly less for MF than for D ( P =.018 and P =.012, respectively). The Dermatology Life Quality Index (DLQI) score was significantly less for MF than for D at weeks 4 and 5 when corrected for Hospital Anxiety and Depression (HAD) questionnaire scores. Conclusions MF cream significantly reduces radiation dermatitis when applied to the breast during and after radiation therapy. For the first time, we have shown a significantly beneficial effect on quality of life using a validated instrument (DLQI), for a topical steroid cream. We believe that application of this cream should be the standard of care where radiation dermatitis is expected. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|